These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25409596)

  • 1. The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study.
    Kwako LE; Spagnolo PA; Schwandt ML; Thorsell A; George DT; Momenan R; Rio DE; Huestis M; Anizan S; Concheiro M; Sinha R; Heilig M
    Neuropsychopharmacology; 2015 Mar; 40(5):1053-63. PubMed ID: 25409596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects.
    Schwandt ML; Cortes CR; Kwako LE; George DT; Momenan R; Sinha R; Grigoriadis DE; Pich EM; Leggio L; Heilig M
    Neuropsychopharmacology; 2016 Nov; 41(12):2818-2829. PubMed ID: 27109623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the CRF
    Epstein DH; Kennedy AP; Furnari M; Heilig M; Shaham Y; Phillips KA; Preston KL
    Psychopharmacology (Berl); 2016 Dec; 233(23-24):3921-3932. PubMed ID: 27595147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial.
    Morabbi MJ; Razaghi E; Moazen-Zadeh E; Safi-Aghdam H; Zarrindast MR; Vousoghi N; Akhondzadeh S
    Int Clin Psychopharmacol; 2018 Mar; 33(2):111-119. PubMed ID: 29064909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study.
    Kwako LE; George DT; Schwandt ML; Spagnolo PA; Momenan R; Hommer DW; Diamond CA; Sinha R; Shaham Y; Heilig M
    Psychopharmacology (Berl); 2015 Jan; 232(1):295-304. PubMed ID: 25030801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
    Coric V; Feldman HH; Oren DA; Shekhar A; Pultz J; Dockens RC; Wu X; Gentile KA; Huang SP; Emison E; Delmonte T; D'Souza BB; Zimbroff DL; Grebb JA; Goddard AW; Stock EG
    Depress Anxiety; 2010 May; 27(5):417-25. PubMed ID: 20455246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical evidence that corticotropin-releasing factor (CRF) receptor antagonists are promising targets for pharmacological treatment of alcoholism.
    Lowery EG; Thiele TE
    CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):77-86. PubMed ID: 20201818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.
    Zorrilla EP; Heilig M; de Wit H; Shaham Y
    Drug Alcohol Depend; 2013 Mar; 128(3):175-86. PubMed ID: 23294766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticotropin-Releasing Factor receptor 1 (CRF1) antagonism in patients with alcohol use disorder and high anxiety levels: effect on neural response during Trier Social Stress Test video feedback.
    Lee MR; Rio D; Kwako L; George DT; Heilig M; Momenan R
    Neuropsychopharmacology; 2023 Apr; 48(5):816-820. PubMed ID: 36564531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats.
    Cippitelli A; Damadzic R; Singley E; Thorsell A; Ciccocioppo R; Eskay RL; Heilig M
    Pharmacol Biochem Behav; 2012 Jan; 100(3):522-9. PubMed ID: 22036774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings.
    Fox HC; Anderson GM; Tuit K; Hansen J; Kimmerling A; Siedlarz KM; Morgan PT; Sinha R
    Alcohol Clin Exp Res; 2012 Feb; 36(2):351-60. PubMed ID: 21919922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity of Pexacerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist, in Rats and Dogs.
    White MR; Graziano MJ; Sanderson TP
    Int J Toxicol; 2019; 38(2):110-120. PubMed ID: 30760067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate.
    Umhau JC; Schwandt ML; Usala J; Geyer C; Singley E; George DT; Heilig M
    Neuropsychopharmacology; 2011 May; 36(6):1178-86. PubMed ID: 21289601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder.
    Milivojevic V; Angarita GA; Hermes G; Sinha R; Fox HC
    Alcohol Clin Exp Res; 2020 Jul; 44(7):1488-1496. PubMed ID: 32449942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRH-sub-1 receptor antagonists for the treatment of depression and anxiety.
    Ising M; Holsboer F
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):519-28. PubMed ID: 18179304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stress-induced and alcohol cue-induced craving in recently abstinent alcohol-dependent individuals.
    Fox HC; Bergquist KL; Hong KI; Sinha R
    Alcohol Clin Exp Res; 2007 Mar; 31(3):395-403. PubMed ID: 17295723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of recent cocaine and alcohol use affects drug craving and associated responses to stress and drug-related cues.
    Fox HC; Talih M; Malison R; Anderson GM; Kreek MJ; Sinha R
    Psychoneuroendocrinology; 2005 Oct; 30(9):880-91. PubMed ID: 15975729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors.
    Sillaber I; Rammes G; Zimmermann S; Mahal B; Zieglgänsberger W; Wurst W; Holsboer F; Spanagel R
    Science; 2002 May; 296(5569):931-3. PubMed ID: 11988580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychopharmacology. Tackling alcoholism with drugs.
    Miller G
    Science; 2008 Apr; 320(5873):168-70. PubMed ID: 18403685
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.
    Ray LA; Bujarski S; Shoptaw S; Roche DJ; Heinzerling K; Miotto K
    Neuropsychopharmacology; 2017 Aug; 42(9):1776-1788. PubMed ID: 28091532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.